Trial Profile

Neo-BCC trial: Neoadjuvant treatment of difficult to resect, locally advanced basal cell carcinoma (BCC) with Talimogene laherparepvec (T-VEC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talimogene laherparepvec (Primary) ; Talimogene laherparepvec (Primary)
Indications Basal cell cancer
Focus Therapeutic Use
Acronyms Neo-BCC

Most Recent Events

10 May 2023 Status changed from recruiting to completed.
13 Sep 2022 Results of exploratory phase II study (n=18; Between January 2020 and January 2022) assessing efficacy and safety of neoadjuvant treatment with talimogene laherparepvec in patients with primary basal cell carcinoma, presented at the 47th European Society for Medical Oncology Congress.
03 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com